Striking a balance between ADC safety and efficacy
Bioconjugation Insights · 2025
DOI: 10.18609/bci.2025.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugation Insights, 2025. Verfasst von Rakesh Dixit. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
“Continued efforts to educate both clinicians and patients, alongside the adoption of proactive safety management protocols, are essential to advancing the safe and effective use of ADCs in cancer treatments.”On October 9, 2024, Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, spoke to Rakesh Dixit, Cofounder, President and CSO of Regio Biosciences, CEO of Bionavigen, and CSO of Tmab Therapeutics, about the application of ADCs in cancer treatment. This article is based on that interview.
Zitieren
APA
Dixit, R. (2025). Striking a balance between ADC safety and efficacy. Bioconjugation Insights. https://doi.org/10.18609/bci.2025.001
Vancouver
Dixit R. Striking a balance between ADC safety and efficacy. Bioconjugation Insights. 2025. doi:10.18609/bci.2025.001
BibTeX
@article{Dixit2025,
author = {Dixit, Rakesh},
title = {Striking a balance between ADC safety and efficacy},
journal = {Bioconjugation Insights},
year = {2025},
doi = {10.18609/bci.2025.001}
}
EUVIMED